PMID- 34740840
OWN - NLM
STAT- MEDLINE
DCOM- 20211126
LR  - 20211126
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 232
DP  - 2021 Nov
TI  - Combination therapy with immune checkpoint inhibitors in advanced renal cell 
      carcinoma: A meta-analysis of randomized controlled trials.
PG  - 108876
LID - S1521-6616(21)00213-8 [pii]
LID - 10.1016/j.clim.2021.108876 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of immune checkpoint inhibitor 
      combination therapy in advanced renal cell carcinoma (RCC). METHODS: We searched 
      PubMed/Embase/Cochrane Library for relevant randomized controlled trials (RCTs). 
      Clinical outcome measures including overall survival (OS), progression-free 
      survival (PFS), objective response rates (ORRs), and adverse events (AEs) were 
      analyzed by Stata 15.1 software. RESULTS: Seven RCTs involving 3461 patients were 
      included. The pooled hazard ratios of OS and PFS for combination therapy were 
      0.67 (0.53-0.82, p < 0.001) and 0.68 (0.52-0.83, p < 0.001), respectively. Longer 
      OS and PFS for combination therapy was also observed in the PD-L1 expression leve 
      >/=1% group. The pooled odds ratios of ORRs and grade 3 or higher AEs were 2.31 
      (1.61-3.32, p < 0.001) and 0.94 (0.65-1.37, p = 0.753), respectively. 
      CONCLUSIONS: Immune checkpoint inhibitor combination therapy showed more clinical 
      benefit in the first-line treatment for advanced RCC, with a safety profile.
CI  - Copyright (c) 2021 Elsevier Inc. All rights reserved.
FAU - Mo, Dun-Chang
AU  - Mo DC
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China. Electronic address: 
      modunchang2018@163.com.
FAU - Huang, Jian-Feng
AU  - Huang JF
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Luo, Peng-Hui
AU  - Luo PH
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Huang, Shang-Xiao
AU  - Huang SX
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
FAU - Wang, Han-Lei
AU  - Wang HL
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning 530000, Guangxi, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20211102
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*therapeutic use
MH  - Immunotherapy/*methods
MH  - Kidney Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Combination immunotherapy
OT  - Efficacy and safety
OT  - Immune checkpoint inhibitor
OT  - Meta-analysis
OT  - Renal cell carcinoma
EDAT- 2021/11/07 06:00
MHDA- 2021/11/27 06:00
CRDT- 2021/11/06 05:35
PHST- 2021/05/27 00:00 [received]
PHST- 2021/08/17 00:00 [revised]
PHST- 2021/10/27 00:00 [accepted]
PHST- 2021/11/07 06:00 [pubmed]
PHST- 2021/11/27 06:00 [medline]
PHST- 2021/11/06 05:35 [entrez]
AID - S1521-6616(21)00213-8 [pii]
AID - 10.1016/j.clim.2021.108876 [doi]
PST - ppublish
SO  - Clin Immunol. 2021 Nov;232:108876. doi: 10.1016/j.clim.2021.108876. Epub 2021 Nov 
      2.